High risk HPV persists after treatment of genital papillomavirus infection but not after treatment of cervical intraepithelial neoplasia.
BACKGROUND
Knowledge about the natural course of HPV infection is still limited. In this study we investigated the presence of HPV DNA after treatment and clinical clearance of infection.


METHODS
Eighty-two women treated for genital HPV infection at the STD clinic in Uppsala were consecutively selected for the study. After treatment with podophyllotoxin, and in some cases laser vaporization, a cell sample was taken at the follow-up visit 6-12 months after clinical clearance of the lesions as evaluated by colposcopy. Samples were analysed with PCR to detect HPV DNA. As a reference group, women treated for cervical intraepithelial neoplasia (CIN) with laser surgery, either with cone biopsy or vaporization, were followed-up after 6 months for the presence of HPV DNA.


RESULTS
Six to 12 months after clinical clearance of HPV infection, 39 (48%) of the women showed detectable HPV DNA in cell samples from the cervix. Of these, 26 (67%) were found to harbor high risk HPV, six (15%) low risk, and seven (18%) either had more than one HPV type or HPV that could not be classified. All but three of the women treated for CIN (90%) were negative for HPV DNA.


CONCLUSIONS
After clinical clearance of genital HPV infection half of the women had detectable HPV DNA. This does not necessarily imply that transmission to a new partner may occur, but indicates this possibility. Only 10% of the CIN treated women harbored HPV DNA in the cell samples in spite of showing high risk HPV infection before treatment.
Strand
A
A
Department of Dermatology, University Hospital, Uppsala, Sweden.
Wilander
E
E
Zehbe
I
I
Rylander
E
E
D000293:Adolescent; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D015342:DNA Probes; D004279:DNA, Viral / Q000302:isolation & purification; D005260:Female; D006801:Humans; D008875:Middle Aged; D027383:Papillomaviridae / Q000235:genetics*; D030361:Papillomavirus Infections / Q000473:pathology / Q000628:therapy / Q000821:virology*; D011034:Podophyllotoxin / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D012306:Risk; D014412:Tumor Virus Infections / Q000473:pathology / Q000628:therapy / Q000821:virology*; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy / Q000821:virology*; D002578:Uterine Cervical Dysplasia / Q000473:pathology / Q000628:therapy / Q000821:virology*
D000972:Antineoplastic Agents, Phytogenic; D015342:DNA Probes; D004279:DNA, Viral; D011034:Podophyllotoxin